VolitionRx Targets Monthly Cash Burn Below $1 Million in 2027

VolitionRx Limited aims to bring monthly operating cash burn below $1 million in 2027 while pursuing a planned French sepsis rollout. The target comes as the company reported $1.6 million in third-quarter revenue and had about $2.4 million in cash at quarter-end.

Revenue for the third quarter of 2026 was $1.6 million, with $3 million in revenue year to date. VolitionRx plans to draw on revenue, licensing income, grants and loans as sources of partial non-dilutive financing.

DETECSEPS data is intended to support a planned rollout of the sepsis program in France, with potential expansion elsewhere in Europe. VolitionRx is also pursuing a letter of intent with Missionpharma as part of its licensing and commercialization efforts.

Separately, management views French reimbursement for the company’s lung cancer products as a key milestone. Management expects the process to take about six months, followed by temporary reimbursement lasting five years.